Patients with Waldenstrom's macroglobulinemia without mutations in MYD88 tend to have a shorter median survival and a lower probability of response to ibrutinib than do those with MYD88 mutations.
No takes yet. Share an insight, caveat, or question.
Treon et al. (2015) studied this question.